More Weight Loss Linked With More Benefit in STEP-HFpEF
Prespecified analysis of the STEP-HFpEF trial of semaglutide in people with obesity and heart failure with preserved ejection fraction showed a positive link between weight-loss amounts and outcomes.
Medscape Medical News
source https://www.medscape.com/viewarticle/995903?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/995903?src=rss
Comments
Post a Comment